We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASFY Boosts Biological Insect Control Portfolio With AgBiTech
Read MoreHide Full Article
Key Takeaways
BASFY secured AgBiTech acquisition to strengthen its Agricultural Solutions business and bio-insect control.
BASFY gains AgBiTech's tech, boosting pest control and reducing reliance on chemicals.
BASFY expands global reach and R&D pipeline, enhancing integrated pest management capabilities.
BASF SE (BASFY - Free Report) recently completed the acquisition of AgBiTech, marking a significant step in strengthening its Agricultural Solutions business and expanding its biological insect control portfolio. AgBiTech is a global leader in biological crop protection and is known for its expertise in baculovirus-based insecticides that provide highly targeted pest control while maintaining environmental safety.
The acquisition enhances BASFY’s ability to offer sustainable and innovative solutions to farmers who are increasingly seeking alternatives to conventional chemical pesticides. It also aligns with the company’s broader strategy to support more resilient agricultural systems.
The integration of AgBiTech brings advanced research capabilities and a strong pipeline of biological products into BASFY’s portfolio. This allows BASFY to expand its presence in key markets, including Brazil, where AgBiTech already has a footprint. The deal strengthens BASFY’s position in integrated pest management by combining biological and chemical solutions to deliver more effective crop protection.
Through this acquisition, BASFY gains access to AgBiTech’s proprietary technologies and production expertise, which are critical for scaling biological insecticides globally. It is expected to accelerate innovation and improve BASFY’s ability to meet evolving customer demands.
Shares of BASFY are up 37.8% over the past year compared with the industry’s 31.7% rise.
The Zacks Consensus Estimate for DD’s current-year earnings stands at $2.28 per share, implying a 35.8% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average earnings surprise being 6.5%.
The Zacks Consensus Estimate for CMP’s current fiscal-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year rise. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, with the average earnings surprise being 34.8%.
The Zacks Consensus Estimate for JMPLY’s current fiscal-year earnings is pegged at $4.34 per share, indicating a 13.9% year-over-year increase. Shares of JMPLY have jumped 75.5% over the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BASFY Boosts Biological Insect Control Portfolio With AgBiTech
Key Takeaways
BASF SE (BASFY - Free Report) recently completed the acquisition of AgBiTech, marking a significant step in strengthening its Agricultural Solutions business and expanding its biological insect control portfolio. AgBiTech is a global leader in biological crop protection and is known for its expertise in baculovirus-based insecticides that provide highly targeted pest control while maintaining environmental safety.
The acquisition enhances BASFY’s ability to offer sustainable and innovative solutions to farmers who are increasingly seeking alternatives to conventional chemical pesticides. It also aligns with the company’s broader strategy to support more resilient agricultural systems.
The integration of AgBiTech brings advanced research capabilities and a strong pipeline of biological products into BASFY’s portfolio. This allows BASFY to expand its presence in key markets, including Brazil, where AgBiTech already has a footprint. The deal strengthens BASFY’s position in integrated pest management by combining biological and chemical solutions to deliver more effective crop protection.
Through this acquisition, BASFY gains access to AgBiTech’s proprietary technologies and production expertise, which are critical for scaling biological insecticides globally. It is expected to accelerate innovation and improve BASFY’s ability to meet evolving customer demands.
Shares of BASFY are up 37.8% over the past year compared with the industry’s 31.7% rise.
BASFY’s Zacks Rank & Key Picks
BASFY carries a Zacks Rank of #3 (Hold).
Better-ranked stocks in the Basic Materials space include DuPont de Nemours, Inc. (DD - Free Report) , Compass Minerals International, Inc. (CMP - Free Report) and Johnson Matthey plc (JMPLY - Free Report) . DD and CMP sport a Zacks Rank of #1 (Strong Buy), while JMPLY carries a Zacks Rank of #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for DD’s current-year earnings stands at $2.28 per share, implying a 35.8% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average earnings surprise being 6.5%.
The Zacks Consensus Estimate for CMP’s current fiscal-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year rise. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, with the average earnings surprise being 34.8%.
The Zacks Consensus Estimate for JMPLY’s current fiscal-year earnings is pegged at $4.34 per share, indicating a 13.9% year-over-year increase. Shares of JMPLY have jumped 75.5% over the past year.